Theriva Biologics, Inc.
TOVX
$0.21
-$0.01-5.94%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.26M | 11.18M | 1.43M | 1.51M | 1.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.81M | 13.13M | 4.40M | 4.40M | 4.45M |
| Operating Income | -3.81M | -13.13M | -4.40M | -4.40M | -4.45M |
| Income Before Tax | -4.36M | -13.06M | -4.32M | -4.45M | -7.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.36M | -13.06M | -4.32M | -4.45M | -7.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.36M | -13.06M | -4.32M | -4.45M | -7.73M |
| EBIT | -3.81M | -13.13M | -4.40M | -4.40M | -4.45M |
| EBITDA | -3.78M | -13.11M | -4.37M | -4.37M | -4.42M |
| EPS Basic | -0.45 | -1.93 | -1.55 | -1.59 | -6.81 |
| Normalized Basic EPS | -0.24 | -1.21 | -0.97 | -0.95 | -2.36 |
| EPS Diluted | -0.45 | -1.93 | -1.55 | -1.59 | -6.81 |
| Normalized Diluted EPS | -0.24 | -1.21 | -0.97 | -0.95 | -2.36 |
| Average Basic Shares Outstanding | 9.68M | 6.75M | 2.78M | 2.79M | 1.13M |
| Average Diluted Shares Outstanding | 9.68M | 6.75M | 2.78M | 2.79M | 1.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |